Treatment approach used in TK2d found effective in COQ2 deficiency
Mouse models and a first-in-human study support the use of 4-hydroxybenzoic acid in primary coenzyme Q deficiency, a study found.
Mouse models and a first-in-human study support the use of 4-hydroxybenzoic acid in primary coenzyme Q deficiency, a study found.
In patients with TK2d and central nervous system involvement, imaging studies may reveal brain atrophy.
An infant with cholestasis was diagnosed with DGUOK deficiency, a mitochondrial DNA maintenance disorder like TK2d.
A recent study of the ketogenic diet in children with metabolic disorders showed improvements in symptoms and biochemical markers.
Primary mitochondrial diseases can impact one or multiple organ symptoms, and become symptomatic at any age.
A 63-year old man presented with weakness in the eyes and limbs, ultimately being diagnosed with a Twinkle-related disease similar to TK2d.
Four infants with TK2d who received doxecitine and doxribitimine through an early access program displayed marked improvements in symptoms.
Global pharmaceutical company UCB has chosen PANTHERx Rare to distribute doxecitine and doxribtimine for the treatment of TK2d.
Making sure your care team is aware of both TK2d and its differential diagnoses is key to proper care.
A recent case report describes a 59-year-old woman treated for psychiatric symptoms for over 30 years before being diagnosed with TK2d.